Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States
PMDA is regarded among the most stringent regulatory bodies globally
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
The investment case for health technology in India is frequently overstated in one direction and understated in another
he innovation could pave the way for early and low-cost screening of smoking exposure and second-hand smoke biomarkers
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
The event showcased latest breakthroughs in minimally invasive surgery, organ-preservation strategies, and targeted therapies
The new capital is expected to fund the company through 2029
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
Subscribe To Our Newsletter & Stay Updated
